Compare Merck & Co., Inc. (MRK) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $135.4 (market cap $327.94B), while iShares 0 3 Month Treasury Bond ETF trades at $100.56. The key difference: Merck & Co., Inc. pays a 2.56% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SGOV | |
|---|---|---|
Market Cap | $327.94B | — |
Sector | Health | Fixed Income |
52-Week High | $135.55 | $100.74 |
52-Week Low | $77.60 | $100.28 |
Enterprise Value | $374.70B | — |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $132.93, up 1.9% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.58. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while financials show solid revenue growth and profitability, though net income margin remains modest at 4.77%.
The stock presents a favorable risk-reward profile with analyst support and strategic M&A activity driving growth. Key risks include high valuation multiples, competitive pressures in pharma, and execution challenges from recent acquisitions. Institutional buying interest and a stable dividend add to the positive sentiment, but investors should monitor debt levels and pipeline developments.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.52, showing minimal daily movement with a 0.01% gain. The technical outlook is bearish with most indicators signaling sell, while the ETF continues to attract institutional interest as a defensive cash alternative. Recent dividend distributions of $0.30-$0.31 provide steady income, with the fund benefiting from elevated Treasury yields amid ongoing interest rate uncertainty.
The ETF offers principal protection and attractive yield exposure to short-term Treasuries, serving as a safe harbor during market volatility. However, performance remains sensitive to Federal Reserve policy shifts and Treasury yield fluctuations, requiring monitoring of inflation data and rate decisions for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
